The New Drug Application (NDA) for DB-1303/BNT323 for unresectable or metastatic HER2-positive adult breast cancer...

NextCure receives Fast Track Designation for SIM0505 (CDH6 ADC) in ovarian cancer

Celltrion ADC drug candidate CT-P71 receives FDA Fast Track Designation for urothelial carcinoma

Corbus Pharmaceuticals announces broad alignment with FDA on registration path for CRB-701 in second-line HNSCC...

Akari Therapeutics announces strategic partnership with WuXi XDC to advance development of its novel ADC...

Sidewinder Therapeutics announces $137 million series B financing to advance precision bispecific ADCs into clinical...